These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

144 related articles for article (PubMed ID: 32481252)

  • 1. Promising response to a PD-1 inhibitor (sintilimab) in non-small cell lung cancer: A case report.
    Zhang L; Mai W; Hao B; Jiang W; Geng Q
    Medicine (Baltimore); 2020 May; 99(21):e19790. PubMed ID: 32481252
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Initial experience of video-assisted thoracic surgery lobectomy after neoadjuvant chemotherapy plus toripalimab in a patient with locally advanced non-small cell lung cancer: a case report.
    Li W; Zhai C; Che J; Wang W; Liu B
    J Cardiothorac Surg; 2022 Jan; 17(1):10. PubMed ID: 35034650
    [TBL] [Abstract][Full Text] [Related]  

  • 3. NeoSCORE II: three vs four cycles of neoadjuvant sintilimab + chemotherapy for squamous non-small-cell lung cancer.
    Zhang X; Shao M; Yao J; Zhao L; Li L; Chen M; Zhang Y; Liu H; Chen Z; Li B; Wu Z; Fan J; Qiu F
    Future Oncol; 2024 Jan; 20(3):121-129. PubMed ID: 38353107
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Sintilimab plus bevacizumab biosimilar IBI305 and chemotherapy for patients with EGFR-mutated non-squamous non-small-cell lung cancer who progressed on EGFR tyrosine-kinase inhibitor therapy (ORIENT-31): first interim results from a randomised, double-blind, multicentre, phase 3 trial.
    Lu S; Wu L; Jian H; Chen Y; Wang Q; Fang J; Wang Z; Hu Y; Sun M; Han L; Miao L; Ding C; Cui J; Li B; Pan Y; Li X; Ye F; Liu A; Wang K; Cang S; Zhou H; Sun X; Ferry D; Lin Y; Wang S; Zhang W; Zhang C
    Lancet Oncol; 2022 Sep; 23(9):1167-1179. PubMed ID: 35908558
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Neoadjuvant PD-1 inhibitor (Sintilimab) in NSCLC.
    Gao S; Li N; Gao S; Xue Q; Ying J; Wang S; Tao X; Zhao J; Mao Y; Wang B; Shao K; Lei W; Wang D; Lv F; Zhao L; Zhang F; Zhao Z; Su K; Tan F; Gao Y; Sun N; Wu D; Yu Y; Ling Y; Wang Z; Duan C; Tang W; Zhang L; He S; Wu N; Wang J; He J
    J Thorac Oncol; 2020 May; 15(5):816-826. PubMed ID: 32036071
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Toxic epidermal necrolysis induced by sintilimab in a patient with advanced non-small cell lung cancer and comorbid pulmonary tuberculosis: A case report.
    Li G; Gong S; Wang N; Yao X
    Front Immunol; 2022; 13():989966. PubMed ID: 36090976
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Immune checkpoint inhibitor-induced myocarditis in lung cancer patients: a case report of sintilimab-induced myocarditis and a review of the literature.
    Bi H; Ren D; Wang Q; Ding X; Wang H
    Ann Palliat Med; 2021 Jan; 10(1):793-802. PubMed ID: 33545801
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Short-term outcomes of neoadjuvant sintilimab with chemotherapy in stage III non-small cell lung cancer: a case series.
    Fan BS; Wang XT; Di SY; Zhao JH; Chen SY; Zhou SH; Yue CY; Song WA; Gong TQ
    Transl Cancer Res; 2022 Jun; 11(6):1697-1704. PubMed ID: 35836545
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Indirect comparison of sintilimab and other PD-L1 inhibitors for first-line treatment of non-squamous non-small-cell lung cancer.
    Zhang L; Qian Y; Li J; Cui C; Chen L; Qu S; Lu S
    Future Oncol; 2022 May; 18(15):1896-1905. PubMed ID: 35311347
    [TBL] [Abstract][Full Text] [Related]  

  • 10. A case report of remarkable response to association of radiofrequency ablation with subsequent Atezolizumab in stage IV nonsmall cell lung cancer.
    Yin J; Dong J; Gao W; Wang Y
    Medicine (Baltimore); 2018 Nov; 97(44):e13112. PubMed ID: 30383701
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Safety and Efficacy of Neoadjuvant Immune Checkpoint Inhibitor Therapy in Patients with Resectable Non-small-Cell Lung Cancer: A Systematic Review.
    Zhao Z; Gao Y; Xue Q; Gao S; He J
    Target Oncol; 2021 Jul; 16(4):425-434. PubMed ID: 33983556
    [TBL] [Abstract][Full Text] [Related]  

  • 12. [Operability and Pathological Response of Non-Small Cell Lung Cancer (NSCLC) after Neoadjuvant Therapy with Immune Checkpoint Inhibition].
    Lücke E; Ganzert C; Föllner S; Wäsche A; Jechorek D; Schoeder V; Walles T; Genseke P; Schreiber J
    Pneumologie; 2020 Nov; 74(11):766-772. PubMed ID: 32820489
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Neoadjuvant Sintilimab and Chemotherapy for Resectable Stage IIIA Non-Small Cell Lung Cancer.
    Zhang P; Dai J; Sun F; Xia H; He W; Duan L; Liu M; Zhao D; Zhu Y; Jiang G
    Ann Thorac Surg; 2022 Sep; 114(3):949-958. PubMed ID: 35176262
    [TBL] [Abstract][Full Text] [Related]  

  • 14. [A case of complete resection of non-squamous non-small-cell lung cancer after induction chemotherapy using carboplatin, paclitaxel, and bevacizumab].
    Kawaharada Y; Imai K; Minamiya Y; Saito H; Konno H; Fujishima S; Ogawa J
    Gan To Kagaku Ryoho; 2012 Oct; 39(10):1533-7. PubMed ID: 23064066
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Sintilimab induced diabetic ketoacidosis in a patient with small cell lung cancer: A case report and literature review.
    Huang X; Yang M; Wang L; Li L; Zhong X
    Medicine (Baltimore); 2021 May; 100(19):e25795. PubMed ID: 34106616
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Sintilimab, stereotactic body radiotherapy and granulocyte-macrophage colony stimulating factor as second-line therapy for advanced non-small cell lung cancer: safety run-in results of a multicenter, single-arm, phase II trial.
    Ni J; Zhou Y; Wu L; Ai X; Dong X; Chu Q; Han C; Wang X; Zhu Z
    Radiat Oncol; 2021 Sep; 16(1):177. PubMed ID: 34526044
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Pembrolizumab plus chemotherapy versus chemotherapy alone in patients with advanced non-small cell lung cancer without tumor PD-L1 expression: A pooled analysis of 3 randomized controlled trials.
    Borghaei H; Langer CJ; Paz-Ares L; Rodríguez-Abreu D; Halmos B; Garassino MC; Houghton B; Kurata T; Cheng Y; Lin J; Pietanza MC; Piperdi B; Gadgeel SM
    Cancer; 2020 Nov; 126(22):4867-4877. PubMed ID: 32914866
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Significant efficacy and well safety of apatinib combined with radiotherapy in NSCLC: Case report.
    Zhao C; Zhang Q; Qiao W
    Medicine (Baltimore); 2017 Dec; 96(50):e9276. PubMed ID: 29390380
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Switching administration of anti-PD-1 and anti-PD-L1 antibodies as immune checkpoint inhibitor rechallenge in individuals with advanced non-small cell lung cancer: Case series and literature review.
    Kitagawa S; Hakozaki T; Kitadai R; Hosomi Y
    Thorac Cancer; 2020 Jul; 11(7):1927-1933. PubMed ID: 32421224
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Unexpected favorable outcome to sintilimab plus bevacizumab in an EGFR-mutated non-small cell lung cancer patient: A case report.
    Zhang Y; Zhao M; Cao S; Zhang X; Du Y
    Thorac Cancer; 2020 Sep; 11(9):2717-2722. PubMed ID: 32656988
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.